Adriana Weinberg
Concepts (833)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Herpes Zoster Vaccine | 25 | 2025 | 160 | 9.930 |
Why?
| | HIV Infections | 97 | 2025 | 3017 | 9.900 |
Why?
| | Herpes Zoster | 33 | 2025 | 319 | 9.360 |
Why?
| | Herpesvirus 3, Human | 37 | 2025 | 336 | 7.490 |
Why?
| | Cytomegalovirus Infections | 28 | 2024 | 197 | 6.070 |
Why?
| | Influenza Vaccines | 29 | 2021 | 551 | 5.880 |
Why?
| | Immunity, Cellular | 34 | 2025 | 269 | 5.730 |
Why?
| | Antibodies, Viral | 44 | 2024 | 653 | 5.400 |
Why?
| | T-Lymphocytes, Regulatory | 15 | 2025 | 393 | 4.770 |
Why?
| | Cytomegalovirus | 27 | 2024 | 163 | 4.370 |
Why?
| | Pregnancy Complications, Infectious | 24 | 2023 | 406 | 4.260 |
Why?
| | Influenza, Human | 27 | 2021 | 626 | 3.980 |
Why?
| | Antiretroviral Therapy, Highly Active | 22 | 2017 | 285 | 2.850 |
Why?
| | Influenza A Virus, H1N1 Subtype | 13 | 2021 | 151 | 2.600 |
Why?
| | Respiratory Syncytial Virus, Human | 6 | 2025 | 76 | 2.580 |
Why?
| | Vaccines, Attenuated | 23 | 2024 | 130 | 2.560 |
Why?
| | Pneumococcal Infections | 4 | 2022 | 110 | 2.540 |
Why?
| | T-Lymphocyte Subsets | 12 | 2019 | 415 | 2.510 |
Why?
| | Anti-HIV Agents | 18 | 2023 | 859 | 2.460 |
Why?
| | Immunologic Memory | 14 | 2020 | 360 | 2.440 |
Why?
| | T-Lymphocytes | 22 | 2020 | 2002 | 2.420 |
Why?
| | Leukocytes, Mononuclear | 16 | 2025 | 573 | 2.320 |
Why?
| | CD4-Positive T-Lymphocytes | 29 | 2023 | 1110 | 2.150 |
Why?
| | Respiratory Tract Infections | 7 | 2025 | 385 | 2.110 |
Why?
| | Vaccination | 23 | 2024 | 1467 | 1.660 |
Why?
| | Chickenpox | 8 | 2024 | 81 | 1.650 |
Why?
| | Antiviral Agents | 17 | 2023 | 747 | 1.590 |
Why?
| | Chickenpox Vaccine | 11 | 2024 | 74 | 1.580 |
Why?
| | Humans | 236 | 2025 | 141187 | 1.580 |
Why?
| | Interferon-gamma | 20 | 2022 | 792 | 1.560 |
Why?
| | Drug Resistance, Viral | 14 | 2017 | 120 | 1.460 |
Why?
| | HIV | 8 | 2022 | 250 | 1.440 |
Why?
| | Female | 162 | 2025 | 75515 | 1.440 |
Why?
| | Virus Diseases | 4 | 2018 | 215 | 1.370 |
Why?
| | CD8-Positive T-Lymphocytes | 12 | 2019 | 918 | 1.360 |
Why?
| | DNA, Viral | 13 | 2024 | 366 | 1.340 |
Why?
| | Tetanus Toxoid | 4 | 2021 | 37 | 1.310 |
Why?
| | Virus Shedding | 6 | 2017 | 48 | 1.290 |
Why?
| | Pregnancy | 42 | 2025 | 7070 | 1.280 |
Why?
| | Infectious Disease Transmission, Vertical | 10 | 2023 | 186 | 1.270 |
Why?
| | Infant | 42 | 2025 | 9818 | 1.230 |
Why?
| | Influenza A virus | 9 | 2013 | 111 | 1.210 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 7 | 9 | 2009 | 28 | 1.200 |
Why?
| | Influenza B virus | 9 | 2017 | 44 | 1.190 |
Why?
| | Respiratory Syncytial Virus Infections | 2 | 2025 | 130 | 1.180 |
Why?
| | Hepatitis A Vaccines | 5 | 2020 | 15 | 1.170 |
Why?
| | Antibodies, Bacterial | 5 | 2022 | 146 | 1.140 |
Why?
| | Vaccines, Synthetic | 7 | 2025 | 139 | 1.130 |
Why?
| | Adult | 98 | 2025 | 39177 | 1.120 |
Why?
| | Dermatitis, Atopic | 5 | 2020 | 331 | 1.110 |
Why?
| | B-Lymphocytes | 7 | 2021 | 858 | 1.110 |
Why?
| | Cord Blood Stem Cell Transplantation | 3 | 2023 | 101 | 1.100 |
Why?
| | Male | 124 | 2025 | 69783 | 1.090 |
Why?
| | Adjuvants, Immunologic | 8 | 2021 | 238 | 1.090 |
Why?
| | HIV-1 | 13 | 2019 | 895 | 1.030 |
Why?
| | CD4 Lymphocyte Count | 17 | 2019 | 284 | 1.030 |
Why?
| | Antibody Formation | 7 | 2023 | 298 | 1.010 |
Why?
| | Hemagglutination Inhibition Tests | 14 | 2021 | 38 | 1.010 |
Why?
| | Anti-Retroviral Agents | 8 | 2023 | 245 | 0.980 |
Why?
| | Pneumococcal Vaccines | 3 | 2022 | 139 | 0.980 |
Why?
| | Lymphocyte Activation | 26 | 2020 | 1150 | 0.970 |
Why?
| | Transforming Growth Factor beta | 4 | 2025 | 497 | 0.960 |
Why?
| | Gastrointestinal Microbiome | 2 | 2025 | 725 | 0.950 |
Why?
| | Breast Feeding | 4 | 2023 | 444 | 0.940 |
Why?
| | Transforming Growth Factor beta1 | 2 | 2025 | 171 | 0.940 |
Why?
| | Interleukin-2 | 13 | 2022 | 453 | 0.910 |
Why?
| | Vaccines, Inactivated | 10 | 2017 | 68 | 0.900 |
Why?
| | Respiratory Syncytial Viruses | 1 | 2025 | 58 | 0.890 |
Why?
| | Monocytes | 2 | 2025 | 579 | 0.890 |
Why?
| | Enzyme-Linked Immunospot Assay | 6 | 2018 | 37 | 0.890 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2023 | 668 | 0.890 |
Why?
| | Viral Load | 18 | 2023 | 506 | 0.880 |
Why?
| | Viremia | 9 | 2021 | 150 | 0.880 |
Why?
| | Infant, Newborn | 24 | 2025 | 6275 | 0.860 |
Why?
| | HIV Protease Inhibitors | 3 | 2019 | 68 | 0.840 |
Why?
| | Child, Preschool | 35 | 2025 | 11457 | 0.820 |
Why?
| | Immune Reconstitution | 1 | 2023 | 8 | 0.810 |
Why?
| | Child | 54 | 2025 | 22308 | 0.810 |
Why?
| | Epstein-Barr Virus Infections | 5 | 2013 | 98 | 0.810 |
Why?
| | Environmental Exposure | 2 | 2018 | 582 | 0.770 |
Why?
| | Papillomavirus Vaccines | 3 | 2018 | 321 | 0.750 |
Why?
| | Herpesvirus 1, Human | 3 | 2016 | 81 | 0.750 |
Why?
| | Receptors, Tumor Necrosis Factor | 8 | 2001 | 166 | 0.740 |
Why?
| | Double-Blind Method | 17 | 2021 | 1983 | 0.730 |
Why?
| | Adolescent | 54 | 2025 | 22007 | 0.730 |
Why?
| | Cytokines | 12 | 2025 | 2098 | 0.720 |
Why?
| | Middle Aged | 63 | 2024 | 34434 | 0.700 |
Why?
| | Orthomyxoviridae | 3 | 2017 | 40 | 0.700 |
Why?
| | Polymerase Chain Reaction | 12 | 2023 | 1056 | 0.700 |
Why?
| | Young Adult | 29 | 2023 | 13673 | 0.680 |
Why?
| | Latent Tuberculosis | 1 | 2021 | 68 | 0.670 |
Why?
| | Aged | 42 | 2024 | 24574 | 0.670 |
Why?
| | DNA-Directed DNA Polymerase | 4 | 2008 | 47 | 0.660 |
Why?
| | Aged, 80 and over | 18 | 2022 | 7856 | 0.660 |
Why?
| | Vitamin D | 2 | 2024 | 397 | 0.650 |
Why?
| | Rotavirus Infections | 2 | 2017 | 39 | 0.640 |
Why?
| | Herpesvirus 4, Human | 8 | 2014 | 165 | 0.640 |
Why?
| | Viral Proteins | 5 | 2012 | 369 | 0.640 |
Why?
| | Rotavirus Vaccines | 2 | 2017 | 42 | 0.640 |
Why?
| | Immunosuppressive Agents | 7 | 2014 | 854 | 0.620 |
Why?
| | Viral Envelope Proteins | 2 | 2021 | 97 | 0.610 |
Why?
| | Tuberculosis | 5 | 2023 | 285 | 0.600 |
Why?
| | Medroxyprogesterone Acetate | 2 | 2016 | 39 | 0.590 |
Why?
| | Respiratory Syncytial Virus Vaccines | 1 | 2019 | 38 | 0.590 |
Why?
| | Antibodies, Neutralizing | 7 | 2021 | 305 | 0.590 |
Why?
| | RNA, Viral | 9 | 2024 | 693 | 0.590 |
Why?
| | Isoniazid | 5 | 2023 | 61 | 0.580 |
Why?
| | Paramyxoviridae Infections | 2 | 2011 | 12 | 0.570 |
Why?
| | Simplexvirus | 9 | 2016 | 82 | 0.570 |
Why?
| | Human papillomavirus 18 | 1 | 2018 | 16 | 0.570 |
Why?
| | Mycobacterium tuberculosis | 1 | 2021 | 320 | 0.560 |
Why?
| | Human papillomavirus 16 | 1 | 2018 | 32 | 0.560 |
Why?
| | Immunocompromised Host | 9 | 2019 | 203 | 0.560 |
Why?
| | Hepatitis A Antibodies | 2 | 2009 | 3 | 0.560 |
Why?
| | Cryopreservation | 2 | 2010 | 106 | 0.560 |
Why?
| | AIDS-Related Opportunistic Infections | 3 | 2019 | 128 | 0.550 |
Why?
| | Th1 Cells | 1 | 2018 | 139 | 0.540 |
Why?
| | Lymphocyte Subsets | 2 | 2015 | 88 | 0.540 |
Why?
| | Antigens, Viral | 8 | 2017 | 179 | 0.530 |
Why?
| | Immunoconjugates | 2 | 2013 | 125 | 0.530 |
Why?
| | Flow Cytometry | 11 | 2019 | 1197 | 0.520 |
Why?
| | Hospitalization | 6 | 2021 | 2255 | 0.520 |
Why?
| | Immunization, Secondary | 6 | 2017 | 88 | 0.520 |
Why?
| | Age Factors | 9 | 2019 | 3292 | 0.520 |
Why?
| | Mutation | 7 | 2009 | 4013 | 0.510 |
Why?
| | Acyclovir | 6 | 2012 | 95 | 0.500 |
Why?
| | Herpesviridae Infections | 5 | 2013 | 148 | 0.500 |
Why?
| | Premature Birth | 2 | 2019 | 365 | 0.500 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 5 | 1999 | 68 | 0.490 |
Why?
| | Case-Control Studies | 14 | 2024 | 3588 | 0.490 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 372 | 0.480 |
Why?
| | Viral Vaccines | 4 | 2014 | 107 | 0.480 |
Why?
| | Herpes Simplex | 4 | 2016 | 95 | 0.470 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 2011 | 174 | 0.470 |
Why?
| | Reagent Kits, Diagnostic | 2 | 2005 | 35 | 0.460 |
Why?
| | Central Nervous System Viral Diseases | 3 | 2004 | 77 | 0.450 |
Why?
| | Contraceptive Agents, Female | 1 | 2016 | 81 | 0.450 |
Why?
| | B-Lymphocyte Subsets | 1 | 2015 | 77 | 0.440 |
Why?
| | Immunoglobulin G | 7 | 2021 | 900 | 0.440 |
Why?
| | Immunoassay | 5 | 2017 | 113 | 0.440 |
Why?
| | Immunity, Mucosal | 2 | 2012 | 96 | 0.430 |
Why?
| | Injections, Intramuscular | 4 | 2017 | 131 | 0.430 |
Why?
| | Killer Cells, Natural | 4 | 2025 | 469 | 0.430 |
Why?
| | Foscarnet | 6 | 2008 | 20 | 0.430 |
Why?
| | Immunophenotyping | 6 | 2019 | 329 | 0.410 |
Why?
| | Transplant Recipients | 3 | 2024 | 178 | 0.410 |
Why?
| | Antigen-Presenting Cells | 4 | 2022 | 159 | 0.400 |
Why?
| | Gene Expression Profiling | 3 | 2019 | 1764 | 0.400 |
Why?
| | B-Lymphocytes, Regulatory | 1 | 2013 | 3 | 0.400 |
Why?
| | Postpartum Period | 5 | 2022 | 353 | 0.390 |
Why?
| | CD4 Antigens | 2 | 2011 | 141 | 0.390 |
Why?
| | Influenza A Virus, H3N2 Subtype | 4 | 2020 | 46 | 0.390 |
Why?
| | Staphylococcus aureus | 1 | 2017 | 437 | 0.390 |
Why?
| | Reverse Transcriptase Inhibitors | 3 | 2020 | 87 | 0.380 |
Why?
| | Immune Tolerance | 2 | 2013 | 368 | 0.380 |
Why?
| | Alphapapillomavirus | 1 | 2012 | 39 | 0.370 |
Why?
| | Hepatitis A | 1 | 2012 | 26 | 0.370 |
Why?
| | Candida | 3 | 2010 | 41 | 0.370 |
Why?
| | Vaccines, Conjugate | 2 | 2022 | 64 | 0.370 |
Why?
| | Cohort Studies | 11 | 2023 | 5799 | 0.370 |
Why?
| | Cell Proliferation | 6 | 2020 | 2504 | 0.370 |
Why?
| | Placebos | 5 | 2017 | 198 | 0.370 |
Why?
| | Polysaccharides | 2 | 2022 | 87 | 0.360 |
Why?
| | Skin | 1 | 2017 | 765 | 0.360 |
Why?
| | CD28 Antigens | 3 | 2009 | 58 | 0.360 |
Why?
| | Immunity, Innate | 2 | 2025 | 852 | 0.360 |
Why?
| | Metapneumovirus | 1 | 2011 | 15 | 0.360 |
Why?
| | Contraceptive Agents | 1 | 2012 | 66 | 0.360 |
Why?
| | Transplantation | 1 | 2011 | 33 | 0.350 |
Why?
| | Herpesvirus 2, Human | 2 | 2012 | 29 | 0.350 |
Why?
| | Lymphocyte Count | 4 | 2019 | 167 | 0.350 |
Why?
| | Lymphoproliferative Disorders | 1 | 2011 | 60 | 0.350 |
Why?
| | T-Lymphocytes, Helper-Inducer | 7 | 1994 | 136 | 0.340 |
Why?
| | Retrospective Studies | 21 | 2024 | 16273 | 0.340 |
Why?
| | Blood | 2 | 2009 | 113 | 0.340 |
Why?
| | Pregnancy Outcome | 7 | 2021 | 457 | 0.340 |
Why?
| | Nucleosides | 1 | 2010 | 26 | 0.340 |
Why?
| | Drug Therapy, Combination | 6 | 2019 | 1040 | 0.340 |
Why?
| | Antitubercular Agents | 3 | 2023 | 207 | 0.330 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2020 | 257 | 0.320 |
Why?
| | Immunoglobulin A | 4 | 2017 | 214 | 0.320 |
Why?
| | Streptococcus pneumoniae | 2 | 2022 | 169 | 0.320 |
Why?
| | Cytosine | 3 | 2008 | 48 | 0.320 |
Why?
| | Glycoproteins | 2 | 2023 | 356 | 0.320 |
Why?
| | Adaptive Immunity | 2 | 2017 | 173 | 0.320 |
Why?
| | Nucleotides | 1 | 2010 | 127 | 0.320 |
Why?
| | Refrigeration | 1 | 2009 | 12 | 0.310 |
Why?
| | Antidepressive Agents | 3 | 2021 | 254 | 0.310 |
Why?
| | Membrane Glycoproteins | 4 | 2001 | 501 | 0.310 |
Why?
| | Follow-Up Studies | 16 | 2024 | 5200 | 0.310 |
Why?
| | Immunity, Humoral | 2 | 2021 | 117 | 0.310 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 8 | 2021 | 855 | 0.310 |
Why?
| | Organophosphonates | 3 | 2008 | 99 | 0.310 |
Why?
| | Astrocytes | 1 | 2011 | 217 | 0.300 |
Why?
| | Freezing | 1 | 2009 | 88 | 0.300 |
Why?
| | Coculture Techniques | 2 | 2025 | 245 | 0.300 |
Why?
| | Cytomegalovirus Retinitis | 2 | 2013 | 21 | 0.300 |
Why?
| | Tetanus | 2 | 2009 | 27 | 0.290 |
Why?
| | Lopinavir | 3 | 2023 | 31 | 0.290 |
Why?
| | Benzoxazines | 3 | 2023 | 33 | 0.280 |
Why?
| | Time Factors | 18 | 2017 | 6956 | 0.280 |
Why?
| | Interleukin-10 | 3 | 2022 | 310 | 0.280 |
Why?
| | Herpesvirus 7, Human | 2 | 2005 | 6 | 0.280 |
Why?
| | Prospective Studies | 14 | 2024 | 7739 | 0.280 |
Why?
| | Immunogenicity, Vaccine | 4 | 2021 | 34 | 0.280 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2008 | 101 | 0.280 |
Why?
| | Longitudinal Studies | 8 | 2019 | 2902 | 0.280 |
Why?
| | Herpesvirus 6, Human | 2 | 2005 | 14 | 0.280 |
Why?
| | Specimen Handling | 1 | 2009 | 182 | 0.270 |
Why?
| | Glioblastoma | 1 | 2011 | 347 | 0.270 |
Why?
| | Norgestrel | 1 | 2007 | 2 | 0.270 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2017 | 987 | 0.270 |
Why?
| | Interleukins | 2 | 2008 | 248 | 0.270 |
Why?
| | Biomarkers | 7 | 2021 | 4174 | 0.260 |
Why?
| | Apoptosis | 6 | 2011 | 2574 | 0.260 |
Why?
| | Incidence | 9 | 2023 | 2794 | 0.260 |
Why?
| | Nucleic Acid Hybridization | 2 | 2006 | 189 | 0.250 |
Why?
| | Antigens, CD | 5 | 2017 | 539 | 0.250 |
Why?
| | Lung Transplantation | 4 | 2002 | 322 | 0.240 |
Why?
| | Coinfection | 2 | 2019 | 137 | 0.240 |
Why?
| | Fibroblasts | 4 | 2025 | 1020 | 0.230 |
Why?
| | Lymphokines | 5 | 1994 | 133 | 0.230 |
Why?
| | Bone Marrow Transplantation | 2 | 2005 | 294 | 0.230 |
Why?
| | Ritonavir | 2 | 2016 | 75 | 0.230 |
Why?
| | A549 Cells | 1 | 2025 | 74 | 0.220 |
Why?
| | Receptors, OX40 | 8 | 2001 | 15 | 0.220 |
Why?
| | Dexamethasone | 1 | 2007 | 380 | 0.220 |
Why?
| | Cell Survival | 5 | 2010 | 1129 | 0.220 |
Why?
| | Roseolovirus Infections | 1 | 2004 | 8 | 0.220 |
Why?
| | Paramyxoviridae | 1 | 2004 | 2 | 0.220 |
Why?
| | Measles Vaccine | 1 | 2024 | 21 | 0.220 |
Why?
| | Virus Replication | 5 | 2017 | 532 | 0.220 |
Why?
| | RNA, Messenger | 10 | 2011 | 2828 | 0.210 |
Why?
| | BCG Vaccine | 2 | 2023 | 24 | 0.210 |
Why?
| | Forkhead Transcription Factors | 3 | 2011 | 199 | 0.210 |
Why?
| | Ganciclovir | 4 | 2008 | 53 | 0.210 |
Why?
| | Milk, Human | 2 | 2023 | 169 | 0.210 |
Why?
| | Autoimmune Diseases | 3 | 2014 | 464 | 0.210 |
Why?
| | Immunity | 2 | 2020 | 140 | 0.210 |
Why?
| | Brazil | 2 | 2021 | 173 | 0.210 |
Why?
| | Cholecalciferol | 1 | 2024 | 61 | 0.210 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2017 | 256 | 0.210 |
Why?
| | Estradiol | 1 | 2007 | 528 | 0.200 |
Why?
| | Myelin Basic Protein | 4 | 1998 | 44 | 0.200 |
Why?
| | Orthomyxoviridae Infections | 1 | 2004 | 68 | 0.200 |
Why?
| | Abnormalities, Drug-Induced | 1 | 2023 | 29 | 0.200 |
Why?
| | Maternal-Fetal Exchange | 2 | 2016 | 172 | 0.200 |
Why?
| | Acquired Immunodeficiency Syndrome | 2 | 2023 | 235 | 0.200 |
Why?
| | Down-Regulation | 1 | 2025 | 641 | 0.200 |
Why?
| | Kaposi Varicelliform Eruption | 3 | 2011 | 21 | 0.200 |
Why?
| | Long-Term Care | 1 | 2024 | 110 | 0.200 |
Why?
| | Adenoviridae Infections | 1 | 2023 | 19 | 0.200 |
Why?
| | Heart Transplantation | 10 | 2001 | 714 | 0.190 |
Why?
| | Papillomavirus Infections | 2 | 2018 | 380 | 0.190 |
Why?
| | Diabetes Mellitus, Type 1 | 4 | 2013 | 3776 | 0.190 |
Why?
| | Isoxazoles | 2 | 2013 | 54 | 0.190 |
Why?
| | United States | 9 | 2024 | 15220 | 0.190 |
Why?
| | Liver Failure, Acute | 1 | 2023 | 64 | 0.190 |
Why?
| | Zidovudine | 2 | 2015 | 79 | 0.190 |
Why?
| | Lamivudine | 2 | 2015 | 65 | 0.190 |
Why?
| | Herpes Genitalis | 2 | 2012 | 18 | 0.190 |
Why?
| | HIV Integrase Inhibitors | 1 | 2023 | 72 | 0.190 |
Why?
| | Dendritic Cells | 1 | 2025 | 505 | 0.190 |
Why?
| | Risk Factors | 18 | 2024 | 10438 | 0.190 |
Why?
| | Genes, Immediate-Early | 1 | 2002 | 25 | 0.180 |
Why?
| | Cyclopropanes | 2 | 2020 | 71 | 0.180 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 2 | 2013 | 96 | 0.180 |
Why?
| | Lymphocytosis | 1 | 2021 | 11 | 0.180 |
Why?
| | South Africa | 6 | 2020 | 240 | 0.180 |
Why?
| | Genes, Viral | 1 | 2002 | 92 | 0.180 |
Why?
| | Central Nervous System Diseases | 1 | 2002 | 73 | 0.180 |
Why?
| | Alkynes | 2 | 2020 | 63 | 0.180 |
Why?
| | Antigens, Differentiation | 1 | 2001 | 82 | 0.180 |
Why?
| | Tuberculin Test | 1 | 2021 | 36 | 0.180 |
Why?
| | Biliary Atresia | 1 | 2023 | 153 | 0.180 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2002 | 226 | 0.180 |
Why?
| | Interferon-gamma Release Tests | 1 | 2021 | 33 | 0.180 |
Why?
| | Organ Transplantation | 1 | 2024 | 250 | 0.170 |
Why?
| | Cells, Cultured | 11 | 2010 | 4208 | 0.170 |
Why?
| | Phenotype | 7 | 2009 | 3166 | 0.170 |
Why?
| | Maternal Exposure | 1 | 2023 | 202 | 0.170 |
Why?
| | Atazanavir Sulfate | 2 | 2023 | 44 | 0.170 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 76 | 0.170 |
Why?
| | Medication Therapy Management | 1 | 2021 | 79 | 0.170 |
Why?
| | Virus Activation | 3 | 2013 | 86 | 0.170 |
Why?
| | Immunoglobulins | 2 | 2017 | 168 | 0.170 |
Why?
| | Evolution, Molecular | 1 | 2005 | 510 | 0.170 |
Why?
| | North America | 2 | 2023 | 306 | 0.170 |
Why?
| | Receptors, Immunologic | 2 | 2000 | 215 | 0.170 |
Why?
| | Sensitivity and Specificity | 5 | 2009 | 1973 | 0.160 |
Why?
| | HIV Seronegativity | 1 | 2020 | 30 | 0.160 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2002 | 209 | 0.160 |
Why?
| | Virus Cultivation | 3 | 2005 | 31 | 0.160 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2022 | 557 | 0.160 |
Why?
| | Dietary Supplements | 1 | 2024 | 566 | 0.150 |
Why?
| | Heart-Assist Devices | 8 | 2000 | 559 | 0.150 |
Why?
| | Treatment Outcome | 16 | 2017 | 11120 | 0.150 |
Why?
| | T-Cell Antigen Receptor Specificity | 1 | 2019 | 51 | 0.150 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2019 | 80 | 0.150 |
Why?
| | Inflammation | 4 | 2019 | 2890 | 0.150 |
Why?
| | Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 2 | 2017 | 15 | 0.150 |
Why?
| | Eicosanoids | 1 | 2019 | 63 | 0.150 |
Why?
| | Survival Analysis | 6 | 2018 | 1319 | 0.150 |
Why?
| | Abatacept | 2 | 2013 | 56 | 0.150 |
Why?
| | Dose-Response Relationship, Immunologic | 2 | 2016 | 85 | 0.150 |
Why?
| | Cholera Toxin | 1 | 2018 | 31 | 0.150 |
Why?
| | Postoperative Complications | 14 | 2001 | 2797 | 0.150 |
Why?
| | Hospitals | 1 | 2023 | 696 | 0.140 |
Why?
| | Saliva | 2 | 2010 | 245 | 0.140 |
Why?
| | Neurodevelopmental Disorders | 1 | 2021 | 196 | 0.140 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2018 | 71 | 0.140 |
Why?
| | Delayed-Action Preparations | 2 | 2016 | 177 | 0.140 |
Why?
| | Genotype | 6 | 2020 | 1859 | 0.140 |
Why?
| | Latin America | 1 | 2018 | 91 | 0.140 |
Why?
| | Depressive Disorder, Major | 2 | 2013 | 374 | 0.140 |
Why?
| | Cell Movement | 2 | 2001 | 990 | 0.140 |
Why?
| | Lysosomal-Associated Membrane Protein 1 | 1 | 2017 | 6 | 0.140 |
Why?
| | CD4-CD8 Ratio | 2 | 2008 | 24 | 0.140 |
Why?
| | Vaccination Coverage | 1 | 2018 | 96 | 0.130 |
Why?
| | Coronary Artery Bypass | 4 | 2001 | 243 | 0.130 |
Why?
| | Injections, Intradermal | 1 | 2017 | 12 | 0.130 |
Why?
| | Cell Line | 5 | 2009 | 2885 | 0.130 |
Why?
| | Injections, Subcutaneous | 2 | 2016 | 165 | 0.130 |
Why?
| | Nervous System Diseases | 1 | 2020 | 275 | 0.130 |
Why?
| | Paralysis | 1 | 2017 | 70 | 0.130 |
Why?
| | Placenta | 2 | 2021 | 761 | 0.130 |
Why?
| | Arm | 1 | 2017 | 108 | 0.130 |
Why?
| | Seroconversion | 1 | 2017 | 46 | 0.130 |
Why?
| | Africa | 1 | 2017 | 119 | 0.130 |
Why?
| | Kinetics | 3 | 2010 | 1652 | 0.130 |
Why?
| | Nelfinavir | 1 | 2016 | 9 | 0.120 |
Why?
| | Animals | 24 | 2011 | 37657 | 0.120 |
Why?
| | Seizures | 1 | 2020 | 442 | 0.120 |
Why?
| | Clinical Trials as Topic | 2 | 2019 | 1052 | 0.120 |
Why?
| | Adoptive Transfer | 3 | 2002 | 223 | 0.120 |
Why?
| | Cross Reactions | 2 | 2014 | 133 | 0.120 |
Why?
| | Base Sequence | 6 | 2017 | 2180 | 0.120 |
Why?
| | Aging | 3 | 2017 | 1892 | 0.120 |
Why?
| | Liver Transplantation | 1 | 2023 | 766 | 0.120 |
Why?
| | Demography | 2 | 2018 | 296 | 0.120 |
Why?
| | Colorado | 2 | 2023 | 4610 | 0.120 |
Why?
| | Comorbidity | 2 | 2019 | 1662 | 0.120 |
Why?
| | Nevirapine | 1 | 2015 | 18 | 0.120 |
Why?
| | RNA | 1 | 2022 | 930 | 0.120 |
Why?
| | Contraceptives, Oral, Synthetic | 1 | 2015 | 1 | 0.120 |
Why?
| | Nasopharynx | 1 | 2015 | 74 | 0.110 |
Why?
| | Nasal Lavage Fluid | 2 | 2005 | 15 | 0.110 |
Why?
| | Virus Latency | 2 | 2013 | 80 | 0.110 |
Why?
| | Infant, Newborn, Diseases | 1 | 2016 | 113 | 0.110 |
Why?
| | Immunoenzyme Techniques | 2 | 2006 | 209 | 0.110 |
Why?
| | Skin Diseases | 1 | 2016 | 147 | 0.110 |
Why?
| | Neutropenia | 1 | 2015 | 157 | 0.110 |
Why?
| | Transcription, Genetic | 1 | 2021 | 1487 | 0.110 |
Why?
| | Seroepidemiologic Studies | 2 | 2024 | 166 | 0.110 |
Why?
| | Multivariate Analysis | 5 | 2017 | 1490 | 0.110 |
Why?
| | Computational Biology | 1 | 2019 | 661 | 0.110 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 1994 | 97 | 0.110 |
Why?
| | Pandemics | 2 | 2021 | 1653 | 0.110 |
Why?
| | Graft Rejection | 5 | 2001 | 544 | 0.110 |
Why?
| | Physical Fitness | 1 | 2015 | 206 | 0.100 |
Why?
| | Herpesvirus 8, Human | 2 | 2005 | 66 | 0.100 |
Why?
| | Drug Resistance, Multiple, Viral | 1 | 2013 | 10 | 0.100 |
Why?
| | Anemia | 1 | 2015 | 177 | 0.100 |
Why?
| | Feces | 1 | 2017 | 504 | 0.100 |
Why?
| | Progesterone | 2 | 2015 | 260 | 0.100 |
Why?
| | Thrombocytopenia | 1 | 2015 | 208 | 0.100 |
Why?
| | Leukocyte Common Antigens | 2 | 2009 | 90 | 0.100 |
Why?
| | Anesthesiology | 1 | 2016 | 169 | 0.100 |
Why?
| | Polyomavirus Infections | 1 | 2013 | 30 | 0.100 |
Why?
| | Tumor Virus Infections | 1 | 2013 | 50 | 0.100 |
Why?
| | Epitopes | 2 | 2009 | 477 | 0.100 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2014 | 184 | 0.100 |
Why?
| | OX40 Ligand | 4 | 2001 | 10 | 0.100 |
Why?
| | Transcriptome | 1 | 2019 | 1003 | 0.100 |
Why?
| | Mothers | 1 | 2019 | 785 | 0.100 |
Why?
| | Proctitis | 1 | 2012 | 7 | 0.090 |
Why?
| | Oxadiazoles | 1 | 2012 | 33 | 0.090 |
Why?
| | Oxidative Stress | 1 | 2019 | 1330 | 0.090 |
Why?
| | Rats, Inbred Lew | 4 | 1998 | 113 | 0.090 |
Why?
| | Aprotinin | 3 | 1997 | 9 | 0.090 |
Why?
| | HIV Seropositivity | 1 | 2013 | 127 | 0.090 |
Why?
| | Interferon Regulatory Factor-2 | 1 | 2011 | 3 | 0.090 |
Why?
| | Depression | 1 | 2021 | 1483 | 0.090 |
Why?
| | DNA Primase | 1 | 2012 | 47 | 0.090 |
Why?
| | Communicable Diseases | 1 | 2014 | 161 | 0.090 |
Why?
| | Mycophenolic Acid | 1 | 2012 | 118 | 0.090 |
Why?
| | Fluorescent Antibody Technique, Direct | 1 | 2011 | 10 | 0.090 |
Why?
| | Viral Plaque Assay | 3 | 2006 | 34 | 0.090 |
Why?
| | L-Selectin | 2 | 2009 | 24 | 0.090 |
Why?
| | Histocompatibility Testing | 3 | 2001 | 123 | 0.090 |
Why?
| | Receptors, Interleukin-2 | 2 | 1990 | 66 | 0.090 |
Why?
| | CD8 Antigens | 1 | 2011 | 75 | 0.090 |
Why?
| | Guanine | 3 | 2006 | 81 | 0.090 |
Why?
| | Encephalitis, Viral | 2 | 2020 | 45 | 0.090 |
Why?
| | Ribavirin | 1 | 2011 | 82 | 0.090 |
Why?
| | DNA Helicases | 1 | 2012 | 140 | 0.080 |
Why?
| | Immunization Schedule | 3 | 2020 | 203 | 0.080 |
Why?
| | Fluorescent Antibody Technique | 2 | 2016 | 386 | 0.080 |
Why?
| | Parturition | 1 | 2011 | 67 | 0.080 |
Why?
| | Motor Activity | 1 | 2015 | 717 | 0.080 |
Why?
| | Length of Stay | 3 | 2014 | 1254 | 0.080 |
Why?
| | Predictive Value of Tests | 3 | 2005 | 2070 | 0.080 |
Why?
| | Logistic Models | 5 | 2010 | 2086 | 0.080 |
Why?
| | Herpesvirus Vaccines | 1 | 2010 | 4 | 0.080 |
Why?
| | Menstrual Cycle | 1 | 2011 | 134 | 0.080 |
Why?
| | Fetal Blood | 2 | 2019 | 341 | 0.080 |
Why?
| | Algorithms | 3 | 2021 | 1763 | 0.080 |
Why?
| | Herpes Simplex Virus Vaccines | 1 | 2009 | 4 | 0.080 |
Why?
| | Granzymes | 1 | 2009 | 50 | 0.080 |
Why?
| | Pokeweed Mitogens | 1 | 2009 | 7 | 0.080 |
Why?
| | Immune System | 2 | 2008 | 183 | 0.080 |
Why?
| | Human Experimentation | 1 | 2009 | 14 | 0.080 |
Why?
| | Neuralgia, Postherpetic | 1 | 2009 | 40 | 0.080 |
Why?
| | Immunologic Factors | 1 | 2011 | 248 | 0.080 |
Why?
| | Drug Stability | 1 | 2009 | 166 | 0.080 |
Why?
| | Plasma | 2 | 2018 | 220 | 0.070 |
Why?
| | Cost of Illness | 1 | 2011 | 312 | 0.070 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2009 | 194 | 0.070 |
Why?
| | Gene Rearrangement, T-Lymphocyte | 1 | 2008 | 16 | 0.070 |
Why?
| | Nasal Mucosa | 1 | 2009 | 106 | 0.070 |
Why?
| | Mice | 13 | 2011 | 18048 | 0.070 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2014 | 1250 | 0.070 |
Why?
| | Inflammation Mediators | 1 | 2011 | 519 | 0.070 |
Why?
| | Botswana | 2 | 2019 | 11 | 0.070 |
Why?
| | Enzyme Inhibitors | 1 | 2012 | 854 | 0.070 |
Why?
| | Betaherpesvirinae | 1 | 2008 | 1 | 0.070 |
Why?
| | Infant Mortality | 2 | 2019 | 121 | 0.070 |
Why?
| | Genetic Variation | 2 | 2011 | 1000 | 0.070 |
Why?
| | Exodeoxyribonucleases | 1 | 2008 | 22 | 0.070 |
Why?
| | Administration, Intranasal | 1 | 2008 | 92 | 0.070 |
Why?
| | Interleukin-15 | 1 | 2008 | 101 | 0.070 |
Why?
| | Cyclosporine | 2 | 2001 | 265 | 0.070 |
Why?
| | Sarcoma | 1 | 2010 | 190 | 0.070 |
Why?
| | Interleukin-12 | 1 | 2008 | 123 | 0.070 |
Why?
| | Trypan Blue | 1 | 2007 | 6 | 0.070 |
Why?
| | Rats | 5 | 1998 | 5629 | 0.070 |
Why?
| | Didanosine | 1 | 2007 | 13 | 0.070 |
Why?
| | Thymus Gland | 1 | 2008 | 319 | 0.070 |
Why?
| | Gene Expression | 3 | 2006 | 1491 | 0.070 |
Why?
| | In Vitro Techniques | 3 | 2006 | 1093 | 0.070 |
Why?
| | Quality Control | 1 | 2007 | 171 | 0.070 |
Why?
| | Data Interpretation, Statistical | 1 | 2009 | 376 | 0.070 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2010 | 286 | 0.060 |
Why?
| | Multicenter Studies as Topic | 2 | 2006 | 338 | 0.060 |
Why?
| | Inhibitory Concentration 50 | 1 | 2006 | 91 | 0.060 |
Why?
| | Vero Cells | 1 | 2006 | 87 | 0.060 |
Why?
| | Cerebrospinal Fluid | 2 | 2004 | 92 | 0.060 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2011 | 1556 | 0.060 |
Why?
| | Pneumonia | 1 | 2013 | 656 | 0.060 |
Why?
| | Veterans | 1 | 2018 | 1514 | 0.060 |
Why?
| | Transfection | 3 | 2002 | 943 | 0.060 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2012 | 852 | 0.060 |
Why?
| | Drug Interactions | 2 | 2020 | 406 | 0.060 |
Why?
| | Deoxycytidine | 1 | 2007 | 192 | 0.060 |
Why?
| | Opportunistic Infections | 2 | 2014 | 45 | 0.060 |
Why?
| | Protein Structure, Tertiary | 1 | 2008 | 859 | 0.060 |
Why?
| | Hemostatics | 2 | 1997 | 58 | 0.060 |
Why?
| | Risk Assessment | 2 | 2014 | 3490 | 0.060 |
Why?
| | Hemadsorption | 1 | 2005 | 1 | 0.060 |
Why?
| | Cytopathogenic Effect, Viral | 1 | 2005 | 16 | 0.060 |
Why?
| | Disease Models, Animal | 2 | 2011 | 4404 | 0.060 |
Why?
| | Tumor Necrosis Factors | 3 | 2001 | 11 | 0.060 |
Why?
| | Signal Transduction | 2 | 2000 | 5144 | 0.060 |
Why?
| | Evaluation Studies as Topic | 1 | 2005 | 175 | 0.060 |
Why?
| | Gene Products, pol | 1 | 2005 | 6 | 0.060 |
Why?
| | Annexin A5 | 1 | 2004 | 26 | 0.060 |
Why?
| | Clinical Trials, Phase II as Topic | 2 | 2017 | 73 | 0.060 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 2004 | 49 | 0.060 |
Why?
| | Antigens | 2 | 2008 | 362 | 0.060 |
Why?
| | Meningitis, Viral | 1 | 2004 | 20 | 0.060 |
Why?
| | Measles virus | 1 | 2024 | 20 | 0.050 |
Why?
| | Parainfluenza Virus 2, Human | 1 | 2004 | 3 | 0.050 |
Why?
| | Parainfluenza Virus 1, Human | 1 | 2004 | 3 | 0.050 |
Why?
| | Parainfluenza Virus 3, Human | 1 | 2004 | 5 | 0.050 |
Why?
| | Sarcoma, Kaposi | 2 | 2003 | 80 | 0.050 |
Why?
| | Transplantation, Homologous | 2 | 2002 | 413 | 0.050 |
Why?
| | Disease Transmission, Infectious | 1 | 2005 | 69 | 0.050 |
Why?
| | Adenoviruses, Human | 1 | 2004 | 27 | 0.050 |
Why?
| | Emtricitabine | 2 | 2021 | 205 | 0.050 |
Why?
| | Cell Culture Techniques | 1 | 2006 | 368 | 0.050 |
Why?
| | Fatal Outcome | 1 | 2005 | 309 | 0.050 |
Why?
| | Chlamydophila Infections | 1 | 2003 | 5 | 0.050 |
Why?
| | Chlamydophila pneumoniae | 1 | 2003 | 12 | 0.050 |
Why?
| | Measles | 1 | 2024 | 46 | 0.050 |
Why?
| | Immunotherapy, Adoptive | 2 | 2001 | 356 | 0.050 |
Why?
| | Survival Rate | 8 | 2001 | 1970 | 0.050 |
Why?
| | Rilpivirine | 1 | 2023 | 9 | 0.050 |
Why?
| | HLA-DR Antigens | 3 | 2001 | 228 | 0.050 |
Why?
| | Hospital Mortality | 4 | 2001 | 924 | 0.050 |
Why?
| | Arteriosclerosis | 1 | 2003 | 83 | 0.050 |
Why?
| | Portoenterostomy, Hepatic | 1 | 2023 | 42 | 0.050 |
Why?
| | Cell Line, Tumor | 1 | 2011 | 3469 | 0.050 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2010 | 646 | 0.050 |
Why?
| | Bronchiolitis Obliterans | 2 | 2001 | 65 | 0.050 |
Why?
| | Darunavir | 1 | 2023 | 19 | 0.050 |
Why?
| | Herpes Labialis | 1 | 2003 | 8 | 0.050 |
Why?
| | DNA Primers | 3 | 2009 | 510 | 0.050 |
Why?
| | Respirovirus | 1 | 2002 | 6 | 0.050 |
Why?
| | Pregnancy Trimester, First | 1 | 2023 | 138 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 1994 | 335 | 0.050 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2005 | 650 | 0.050 |
Why?
| | Parapsychology | 1 | 2001 | 1 | 0.050 |
Why?
| | Risk | 1 | 2005 | 904 | 0.050 |
Why?
| | Adenoviridae | 1 | 2023 | 201 | 0.050 |
Why?
| | Electromagnetic Fields | 1 | 2001 | 38 | 0.050 |
Why?
| | Zimbabwe | 2 | 2017 | 61 | 0.050 |
Why?
| | B7-1 Antigen | 2 | 1998 | 58 | 0.040 |
Why?
| | Microbial Sensitivity Tests | 1 | 2003 | 370 | 0.040 |
Why?
| | Ovalbumin | 1 | 2001 | 196 | 0.040 |
Why?
| | Cobicistat | 1 | 2021 | 5 | 0.040 |
Why?
| | Molecular Sequence Data | 4 | 1994 | 2929 | 0.040 |
Why?
| | Receptors, CXCR5 | 1 | 2021 | 23 | 0.040 |
Why?
| | CTLA-4 Antigen | 1 | 2001 | 101 | 0.040 |
Why?
| | Rituximab | 2 | 2013 | 204 | 0.040 |
Why?
| | Antibody Affinity | 1 | 2021 | 60 | 0.040 |
Why?
| | Photography | 1 | 2001 | 115 | 0.040 |
Why?
| | Liver Diseases | 1 | 2024 | 301 | 0.040 |
Why?
| | Vaccines, Subunit | 1 | 2021 | 50 | 0.040 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2002 | 128 | 0.040 |
Why?
| | Lymphoma | 1 | 2002 | 228 | 0.040 |
Why?
| | Prostheses and Implants | 3 | 1996 | 144 | 0.040 |
Why?
| | Equivalence Trials as Topic | 1 | 2020 | 12 | 0.040 |
Why?
| | Arylamine N-Acetyltransferase | 1 | 2020 | 7 | 0.040 |
Why?
| | Cytochrome P-450 CYP2B6 | 1 | 2020 | 10 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 1990 | 2599 | 0.040 |
Why?
| | Models, Statistical | 1 | 2005 | 671 | 0.040 |
Why?
| | Pre-Eclampsia | 1 | 2023 | 202 | 0.040 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2001 | 115 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2016 | 1320 | 0.040 |
Why?
| | Living Donors | 1 | 2023 | 268 | 0.040 |
Why?
| | Metabolic Clearance Rate | 1 | 2020 | 116 | 0.040 |
Why?
| | Spinal Cord | 2 | 1994 | 373 | 0.040 |
Why?
| | Surface Properties | 1 | 2001 | 412 | 0.040 |
Why?
| | Heart Failure | 3 | 1999 | 2088 | 0.040 |
Why?
| | Glioma | 1 | 2005 | 427 | 0.040 |
Why?
| | DNA | 2 | 2006 | 1444 | 0.040 |
Why?
| | Central Nervous System Neoplasms | 1 | 2002 | 169 | 0.040 |
Why?
| | Alanine | 1 | 2021 | 153 | 0.040 |
Why?
| | Trans-Activators | 1 | 2002 | 388 | 0.040 |
Why?
| | Lymphatic Metastasis | 1 | 2001 | 326 | 0.040 |
Why?
| | Confusion | 1 | 2020 | 30 | 0.040 |
Why?
| | Cancer Vaccines | 1 | 2001 | 167 | 0.040 |
Why?
| | Hemodynamics | 3 | 2001 | 1100 | 0.040 |
Why?
| | Coronary Disease | 2 | 2001 | 371 | 0.040 |
Why?
| | Antibodies | 1 | 2001 | 409 | 0.040 |
Why?
| | Interleukin-3 | 3 | 1994 | 24 | 0.040 |
Why?
| | Prognosis | 3 | 2024 | 4073 | 0.040 |
Why?
| | Liver Function Tests | 1 | 2019 | 105 | 0.040 |
Why?
| | Acetates | 1 | 2019 | 79 | 0.040 |
Why?
| | California | 2 | 2015 | 462 | 0.040 |
Why?
| | Candidiasis | 1 | 1999 | 63 | 0.040 |
Why?
| | Triiodothyronine | 1 | 1999 | 50 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 2 | 1999 | 672 | 0.040 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2019 | 70 | 0.040 |
Why?
| | Hemagglutination | 1 | 2018 | 8 | 0.040 |
Why?
| | Macrophage-1 Antigen | 1 | 1999 | 28 | 0.040 |
Why?
| | Tenofovir | 1 | 2021 | 276 | 0.040 |
Why?
| | Cross-Sectional Studies | 3 | 2024 | 5636 | 0.040 |
Why?
| | Arginine Vasopressin | 1 | 1998 | 43 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2011 | 2132 | 0.040 |
Why?
| | Hypoplastic Left Heart Syndrome | 1 | 2000 | 118 | 0.040 |
Why?
| | Mice, Inbred BALB C | 1 | 2001 | 1274 | 0.040 |
Why?
| | Brain Diseases | 1 | 2020 | 149 | 0.040 |
Why?
| | Neoplasms | 3 | 2001 | 2741 | 0.040 |
Why?
| | Adenine | 1 | 2021 | 301 | 0.040 |
Why?
| | Pilot Projects | 1 | 2024 | 1820 | 0.040 |
Why?
| | Haptoglobins | 1 | 2018 | 56 | 0.040 |
Why?
| | Quinazolines | 1 | 2019 | 250 | 0.040 |
Why?
| | HLA-B Antigens | 1 | 1998 | 64 | 0.030 |
Why?
| | Vasoconstrictor Agents | 1 | 1998 | 134 | 0.030 |
Why?
| | Chronic Disease | 1 | 2024 | 1816 | 0.030 |
Why?
| | Antibody Specificity | 1 | 1998 | 187 | 0.030 |
Why?
| | Delivery, Obstetric | 1 | 2019 | 163 | 0.030 |
Why?
| | Protein Precursors | 1 | 2018 | 133 | 0.030 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2017 | 51 | 0.030 |
Why?
| | Shock | 1 | 1998 | 103 | 0.030 |
Why?
| | Inositol Phosphates | 1 | 2017 | 22 | 0.030 |
Why?
| | Sterols | 1 | 2017 | 20 | 0.030 |
Why?
| | Immunization | 1 | 2020 | 406 | 0.030 |
Why?
| | Autogenic Training | 1 | 1997 | 1 | 0.030 |
Why?
| | Proviruses | 1 | 2017 | 16 | 0.030 |
Why?
| | Radioactive Fallout | 1 | 1997 | 1 | 0.030 |
Why?
| | Leukemia, Radiation-Induced | 1 | 1997 | 4 | 0.030 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2017 | 68 | 0.030 |
Why?
| | Radioactive Hazard Release | 1 | 1997 | 3 | 0.030 |
Why?
| | Sequence Analysis | 1 | 2017 | 36 | 0.030 |
Why?
| | Power Plants | 1 | 1997 | 9 | 0.030 |
Why?
| | Zambia | 1 | 2017 | 57 | 0.030 |
Why?
| | Relaxation Therapy | 1 | 1997 | 19 | 0.030 |
Why?
| | Tanzania | 1 | 2017 | 59 | 0.030 |
Why?
| | Observational Studies as Topic | 1 | 2017 | 123 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2005 | 3348 | 0.030 |
Why?
| | Encephalitis | 1 | 1998 | 137 | 0.030 |
Why?
| | Lung Injury | 1 | 2000 | 227 | 0.030 |
Why?
| | Ligands | 1 | 1999 | 667 | 0.030 |
Why?
| | Heart Valves | 1 | 1997 | 42 | 0.030 |
Why?
| | Aortic Valve Insufficiency | 1 | 1996 | 44 | 0.030 |
Why?
| | Prevalence | 2 | 2018 | 2772 | 0.030 |
Why?
| | Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2016 | 25 | 0.030 |
Why?
| | Erythema | 1 | 2016 | 28 | 0.030 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 1997 | 103 | 0.030 |
Why?
| | Body Weight | 1 | 2020 | 996 | 0.030 |
Why?
| | Fiber Optic Technology | 1 | 2016 | 24 | 0.030 |
Why?
| | Up-Regulation | 2 | 2001 | 859 | 0.030 |
Why?
| | Heart Arrest, Induced | 1 | 1995 | 34 | 0.030 |
Why?
| | Thromboembolism | 1 | 1996 | 118 | 0.030 |
Why?
| | Graft vs Host Disease | 1 | 1998 | 254 | 0.030 |
Why?
| | Chi-Square Distribution | 2 | 2013 | 521 | 0.030 |
Why?
| | Intestines | 1 | 2018 | 357 | 0.030 |
Why?
| | Vasodilation | 1 | 1998 | 516 | 0.030 |
Why?
| | Single-Blind Method | 1 | 2016 | 288 | 0.030 |
Why?
| | Reference Values | 2 | 2011 | 805 | 0.030 |
Why?
| | Registries | 1 | 2024 | 2135 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2002 | 1478 | 0.030 |
Why?
| | Blood Transfusion | 2 | 1995 | 392 | 0.030 |
Why?
| | Interleukin-4 | 2 | 1998 | 215 | 0.030 |
Why?
| | Ovulation | 1 | 2015 | 40 | 0.030 |
Why?
| | Liver | 1 | 2023 | 1819 | 0.030 |
Why?
| | Antibodies, Monoclonal | 2 | 2001 | 1448 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2017 | 313 | 0.030 |
Why?
| | Cross Infection | 1 | 1997 | 254 | 0.030 |
Why?
| | Hematologic Neoplasms | 1 | 1997 | 159 | 0.030 |
Why?
| | Hypothermia, Induced | 1 | 1995 | 92 | 0.030 |
Why?
| | Rats, Inbred BUF | 1 | 1994 | 1 | 0.030 |
Why?
| | Blood Loss, Surgical | 1 | 1995 | 112 | 0.030 |
Why?
| | HLA-A2 Antigen | 1 | 2014 | 49 | 0.030 |
Why?
| | Surgical Wound Infection | 1 | 1997 | 319 | 0.030 |
Why?
| | Aortic Coarctation | 1 | 1994 | 80 | 0.030 |
Why?
| | Polymorphism, Restriction Fragment Length | 2 | 2003 | 68 | 0.030 |
Why?
| | Quality of Life | 4 | 2000 | 2999 | 0.030 |
Why?
| | Pulmonary Emphysema | 1 | 1996 | 312 | 0.030 |
Why?
| | Myocardial Infarction | 1 | 2001 | 1069 | 0.030 |
Why?
| | Colony-Stimulating Factors | 2 | 1990 | 37 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2016 | 578 | 0.030 |
Why?
| | Aortic Valve | 1 | 1996 | 359 | 0.030 |
Why?
| | Cause of Death | 3 | 2001 | 440 | 0.020 |
Why?
| | BK Virus | 1 | 2013 | 16 | 0.020 |
Why?
| | Intubation, Intratracheal | 1 | 2016 | 286 | 0.020 |
Why?
| | Growth Substances | 2 | 1990 | 148 | 0.020 |
Why?
| | JC Virus | 1 | 2013 | 23 | 0.020 |
Why?
| | Herpesviridae | 1 | 2012 | 22 | 0.020 |
Why?
| | Mice, Inbred Strains | 2 | 1990 | 412 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 2 | 2011 | 2363 | 0.020 |
Why?
| | Drug Administration Schedule | 2 | 2007 | 771 | 0.020 |
Why?
| | Cardiac Surgical Procedures | 1 | 1998 | 585 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 1990 | 159 | 0.020 |
Why?
| | Hypersensitivity, Delayed | 1 | 1992 | 30 | 0.020 |
Why?
| | Heart Diseases | 1 | 1995 | 335 | 0.020 |
Why?
| | Ventricular Function, Left | 1 | 1995 | 513 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2001 | 1787 | 0.020 |
Why?
| | Brain Neoplasms | 1 | 2001 | 1304 | 0.020 |
Why?
| | Spleen | 1 | 1994 | 525 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 908 | 0.020 |
Why?
| | Ambulatory Care | 1 | 1996 | 582 | 0.020 |
Why?
| | Patient Selection | 1 | 1995 | 688 | 0.020 |
Why?
| | Sex Characteristics | 1 | 2017 | 788 | 0.020 |
Why?
| | Metabolomics | 1 | 2017 | 704 | 0.020 |
Why?
| | Histocompatibility Antigens | 1 | 1992 | 107 | 0.020 |
Why?
| | Computer Simulation | 1 | 2016 | 1015 | 0.020 |
Why?
| | Matched-Pair Analysis | 1 | 2011 | 38 | 0.020 |
Why?
| | Receptors, Interferon | 1 | 2011 | 52 | 0.020 |
Why?
| | Stroke | 1 | 2000 | 1154 | 0.020 |
Why?
| | Administration, Oral | 1 | 2013 | 803 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 1997 | 596 | 0.020 |
Why?
| | Age of Onset | 1 | 2012 | 532 | 0.020 |
Why?
| | Radiotherapy | 2 | 2005 | 208 | 0.020 |
Why?
| | Cattle | 2 | 1990 | 998 | 0.020 |
Why?
| | Lung Neoplasms | 2 | 2001 | 2560 | 0.020 |
Why?
| | Polyribosomes | 1 | 1990 | 24 | 0.020 |
Why?
| | Cell Separation | 1 | 2011 | 317 | 0.020 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 1990 | 156 | 0.020 |
Why?
| | Concanavalin A | 1 | 1990 | 75 | 0.020 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 1990 | 156 | 0.020 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 1990 | 92 | 0.020 |
Why?
| | Blotting, Northern | 1 | 1990 | 198 | 0.020 |
Why?
| | Haplotypes | 1 | 2011 | 496 | 0.020 |
Why?
| | Infant, Premature | 1 | 2014 | 597 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2011 | 372 | 0.020 |
Why?
| | Papillomaviridae | 1 | 2010 | 133 | 0.020 |
Why?
| | beta-Globins | 1 | 2009 | 8 | 0.020 |
Why?
| | Mice, Knockout | 2 | 2011 | 3068 | 0.020 |
Why?
| | Herpesvirus 1, Bovine | 1 | 1989 | 3 | 0.020 |
Why?
| | Cell Division | 2 | 2002 | 798 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1597 | 0.020 |
Why?
| | Anxiety | 1 | 1997 | 1082 | 0.020 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2016 | 662 | 0.020 |
Why?
| | Ribosomes | 1 | 1990 | 186 | 0.020 |
Why?
| | Immunoglobulin E | 1 | 2010 | 331 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2011 | 761 | 0.020 |
Why?
| | Hematopoietic Stem Cells | 2 | 1990 | 411 | 0.020 |
Why?
| | Arthritis, Rheumatoid | 1 | 1998 | 1176 | 0.020 |
Why?
| | Reference Standards | 1 | 2009 | 186 | 0.020 |
Why?
| | Phylogeny | 1 | 2013 | 1018 | 0.020 |
Why?
| | Multiple Sclerosis | 1 | 1994 | 468 | 0.020 |
Why?
| | Linear Models | 1 | 2010 | 857 | 0.020 |
Why?
| | Infusions, Intravenous | 2 | 1999 | 417 | 0.020 |
Why?
| | Membrane Proteins | 1 | 1994 | 1154 | 0.020 |
Why?
| | Clinical Competence | 1 | 2016 | 1202 | 0.020 |
Why?
| | Protein Biosynthesis | 1 | 1990 | 444 | 0.020 |
Why?
| | Time | 1 | 2007 | 87 | 0.020 |
Why?
| | Kidney Transplantation | 1 | 2013 | 675 | 0.020 |
Why?
| | Drug Resistance, Multiple | 1 | 2006 | 25 | 0.020 |
Why?
| | Antineoplastic Agents | 2 | 2010 | 2166 | 0.020 |
Why?
| | Clinical Protocols | 1 | 2007 | 273 | 0.010 |
Why?
| | Templates, Genetic | 1 | 2005 | 63 | 0.010 |
Why?
| | Cell Differentiation | 4 | 2000 | 2003 | 0.010 |
Why?
| | Postoperative Care | 2 | 1999 | 279 | 0.010 |
Why?
| | Codon | 1 | 2005 | 92 | 0.010 |
Why?
| | Internship and Residency | 1 | 2016 | 1235 | 0.010 |
Why?
| | Interleukin-5 | 2 | 1998 | 42 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2009 | 1498 | 0.010 |
Why?
| | DNA Replication | 1 | 2006 | 240 | 0.010 |
Why?
| | Mice, Transgenic | 2 | 2000 | 2180 | 0.010 |
Why?
| | Age Distribution | 1 | 2005 | 395 | 0.010 |
Why?
| | Sex Distribution | 1 | 2005 | 379 | 0.010 |
Why?
| | Creatinine | 2 | 1997 | 489 | 0.010 |
Why?
| | Vaccines | 1 | 2009 | 406 | 0.010 |
Why?
| | Abdominal Neoplasms | 1 | 2003 | 47 | 0.010 |
Why?
| | Lung | 1 | 1996 | 4134 | 0.010 |
Why?
| | Endemic Diseases | 1 | 2003 | 36 | 0.010 |
Why?
| | Disease Progression | 1 | 2010 | 2793 | 0.010 |
Why?
| | Peptide Fragments | 2 | 1998 | 698 | 0.010 |
Why?
| | Neuroblastoma | 1 | 2003 | 163 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2005 | 824 | 0.010 |
Why?
| | Bioelectric Energy Sources | 1 | 2001 | 4 | 0.010 |
Why?
| | Fibrosarcoma | 1 | 2001 | 21 | 0.010 |
Why?
| | Electricity | 1 | 2001 | 24 | 0.010 |
Why?
| | Galvanic Skin Response | 1 | 2001 | 25 | 0.010 |
Why?
| | Electric Conductivity | 1 | 2001 | 86 | 0.010 |
Why?
| | Actuarial Analysis | 1 | 2001 | 22 | 0.010 |
Why?
| | Injections, Intravenous | 1 | 2001 | 202 | 0.010 |
Why?
| | Anticoagulants | 2 | 1996 | 675 | 0.010 |
Why?
| | Melanoma, Experimental | 1 | 2001 | 111 | 0.010 |
Why?
| | Fingers | 1 | 2001 | 106 | 0.010 |
Why?
| | HLA-A Antigens | 1 | 2001 | 58 | 0.010 |
Why?
| | Myocardial Revascularization | 1 | 2001 | 74 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 2001 | 434 | 0.010 |
Why?
| | Immune Sera | 1 | 2000 | 84 | 0.010 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2003 | 450 | 0.010 |
Why?
| | Amino Acid Sequence | 2 | 1994 | 2158 | 0.010 |
Why?
| | Probability | 1 | 2001 | 309 | 0.010 |
Why?
| | Mice, Inbred C57BL | 2 | 2001 | 5887 | 0.010 |
Why?
| | Clone Cells | 1 | 2000 | 266 | 0.010 |
Why?
| | Databases as Topic | 1 | 2000 | 69 | 0.010 |
Why?
| | Emergency Treatment | 1 | 2001 | 125 | 0.010 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2001 | 208 | 0.010 |
Why?
| | New York | 1 | 2000 | 127 | 0.010 |
Why?
| | Carotid Artery Diseases | 1 | 2000 | 62 | 0.010 |
Why?
| | Students | 1 | 2005 | 645 | 0.010 |
Why?
| | Peripheral Vascular Diseases | 1 | 2000 | 103 | 0.010 |
Why?
| | Columbidae | 1 | 1998 | 31 | 0.010 |
Why?
| | Cytochrome c Group | 1 | 1998 | 44 | 0.010 |
Why?
| | Cardiotonic Agents | 1 | 1999 | 95 | 0.010 |
Why?
| | Lymph Nodes | 1 | 2001 | 502 | 0.010 |
Why?
| | Cardiac Output | 1 | 1999 | 177 | 0.010 |
Why?
| | Life Tables | 1 | 1998 | 20 | 0.010 |
Why?
| | Temperature | 1 | 2001 | 669 | 0.010 |
Why?
| | Endocardium | 1 | 1998 | 31 | 0.010 |
Why?
| | Aortic Diseases | 1 | 2000 | 119 | 0.010 |
Why?
| | Vascular Resistance | 1 | 1999 | 364 | 0.010 |
Why?
| | Calcinosis | 1 | 2000 | 238 | 0.010 |
Why?
| | Cell Death | 1 | 1999 | 386 | 0.010 |
Why?
| | Hypotension | 1 | 1998 | 122 | 0.010 |
Why?
| | Cardiopulmonary Bypass | 1 | 2000 | 218 | 0.010 |
Why?
| | Renal Insufficiency | 1 | 2000 | 169 | 0.010 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 1998 | 198 | 0.010 |
Why?
| | Phosphorylation | 1 | 2002 | 1768 | 0.010 |
Why?
| | Ukraine | 1 | 1997 | 22 | 0.010 |
Why?
| | Endocarditis, Bacterial | 1 | 1997 | 46 | 0.010 |
Why?
| | Odds Ratio | 1 | 2000 | 1052 | 0.010 |
Why?
| | Models, Structural | 1 | 1996 | 41 | 0.010 |
Why?
| | Lung Volume Measurements | 1 | 1996 | 47 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2001 | 2064 | 0.010 |
Why?
| | Radiometry | 1 | 1997 | 54 | 0.010 |
Why?
| | Histocompatibility Antigens Class II | 1 | 1998 | 369 | 0.010 |
Why?
| | Epidemiologic Methods | 1 | 1997 | 96 | 0.010 |
Why?
| | Ultrasonography, Doppler, Transcranial | 1 | 1996 | 44 | 0.010 |
Why?
| | Cardiac Output, Low | 1 | 1996 | 46 | 0.010 |
Why?
| | Health Care Costs | 1 | 2000 | 424 | 0.010 |
Why?
| | Equipment Failure | 1 | 1996 | 111 | 0.010 |
Why?
| | Urogenital Neoplasms | 1 | 1995 | 5 | 0.010 |
Why?
| | Europe | 1 | 1997 | 410 | 0.010 |
Why?
| | Pneumonia, Viral | 1 | 2001 | 374 | 0.010 |
Why?
| | Vital Capacity | 1 | 1996 | 312 | 0.010 |
Why?
| | Neoplasms, Second Primary | 1 | 1997 | 109 | 0.010 |
Why?
| | Heart Valve Prosthesis | 1 | 1997 | 115 | 0.010 |
Why?
| | Models, Cardiovascular | 1 | 1996 | 197 | 0.010 |
Why?
| | Blood Urea Nitrogen | 1 | 1995 | 54 | 0.010 |
Why?
| | Forced Expiratory Volume | 1 | 1996 | 489 | 0.010 |
Why?
| | Heart Rate | 1 | 1999 | 821 | 0.010 |
Why?
| | Acute Disease | 1 | 1998 | 1008 | 0.010 |
Why?
| | Aortic Aneurysm | 1 | 1995 | 70 | 0.010 |
Why?
| | Child Development | 1 | 2000 | 498 | 0.010 |
Why?
| | Hodgkin Disease | 1 | 1997 | 157 | 0.010 |
Why?
| | Equipment Design | 1 | 1996 | 525 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 1998 | 1261 | 0.010 |
Why?
| | Biopsy | 1 | 1998 | 1081 | 0.010 |
Why?
| | Waiting Lists | 1 | 1996 | 244 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 1998 | 720 | 0.010 |
Why?
| | Heart Septal Defects, Ventricular | 1 | 1994 | 45 | 0.010 |
Why?
| | Interviews as Topic | 1 | 1997 | 844 | 0.010 |
Why?
| | Reoperation | 1 | 1997 | 588 | 0.010 |
Why?
| | Pain, Postoperative | 1 | 1997 | 309 | 0.010 |
Why?
| | Exercise Test | 1 | 1996 | 625 | 0.010 |
Why?
| | Cell Adhesion | 1 | 1994 | 468 | 0.010 |
Why?
| | Myocardium | 1 | 1998 | 928 | 0.010 |
Why?
| | Thyroid Neoplasms | 1 | 1997 | 327 | 0.010 |
Why?
| | Ventricular Function, Right | 1 | 1995 | 283 | 0.010 |
Why?
| | Central Nervous System | 1 | 1994 | 265 | 0.010 |
Why?
| | Patient Compliance | 1 | 1997 | 610 | 0.010 |
Why?
| | Feasibility Studies | 1 | 1996 | 1018 | 0.010 |
Why?
| | Smoking | 1 | 2000 | 1601 | 0.010 |
Why?
| | Blood Pressure | 1 | 1998 | 1748 | 0.010 |
Why?
| | Diabetes Mellitus | 1 | 2000 | 1074 | 0.010 |
Why?
| | Head and Neck Neoplasms | 1 | 1995 | 553 | 0.010 |
Why?
| | Lymphocyte Cooperation | 1 | 1990 | 49 | 0.010 |
Why?
| | Receptors, Lymphocyte Homing | 1 | 1990 | 16 | 0.010 |
Why?
| | Thymectomy | 1 | 1990 | 15 | 0.010 |
Why?
| | Research Design | 1 | 1997 | 1143 | 0.010 |
Why?
| | Antilymphocyte Serum | 1 | 1990 | 59 | 0.010 |
Why?
| | Antigens, Surface | 1 | 1990 | 156 | 0.000 |
Why?
| | Infectious Bovine Rhinotracheitis | 1 | 1989 | 1 | 0.000 |
Why?
| | Phorbol Esters | 1 | 1989 | 14 | 0.000 |
Why?
| | Ionomycin | 1 | 1989 | 22 | 0.000 |
Why?
| | Rabbits | 1 | 1990 | 754 | 0.000 |
Why?
| | Ethers | 1 | 1989 | 19 | 0.000 |
Why?
| | Immunotherapy | 1 | 1994 | 640 | 0.000 |
Why?
| | Isoantigens | 1 | 1988 | 17 | 0.000 |
Why?
| | Kidney | 1 | 1997 | 1482 | 0.000 |
Why?
| | Cell-Free System | 1 | 1988 | 55 | 0.000 |
Why?
| | Surveys and Questionnaires | 1 | 2000 | 5929 | 0.000 |
Why?
| | Breast Neoplasms | 1 | 1997 | 2250 | 0.000 |
Why?
| | Models, Biological | 1 | 1988 | 1828 | 0.000 |
Why?
|
|
Weinberg's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|